Daiichi Move Aids Global Competition With U.S., Israel
This article was originally published in PharmAsia News
The move by Japan's Daiichi Sankyo to buy India's largest pharmaceutical firm, Ranbaxy Laboratories, is seen as aiding the Japanese firm's efforts to compete with U.S. and Israeli rivals in the global drug market. By merging with Ranbaxy, Daiichi becomes the world's 15th largest drug maker, giving it access to Ranbaxy's generics empire, particularly in the United States where Daiichi has not been much of a player. By buying Ranbaxy, Daiichi is positioning itself in the U.S. market to be a major supplier in a generics market that comprises nearly half of U.S. prescriptions. (Click here for more
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.